Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)
February 1, 2023 01:28 PM ESTUpdated February 2, 06:47 AM
Pharma

Go­ing block­buster hunt­ing, Vas Narasimhan out­lines vi­sion for ‘pure-play’ No­var­tis

Amber Tong

By the time 2023 is over, No­var­tis ex­pects to be mov­ing much lighter: It will have spun out its gener­ics sub­sidiary San­doz, com­plet­ed lay­offs of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Less than two years af­ter block­buster IPO, Ace­lyrin merges with Alu­mis to com­bine cash, as­sets

Long­time San­doz ex­ec an­nounces re­tire­ment; Lil­ly ap­points head of In­dia

Bris­tol My­ers prunes pipeline amid new round of cost cuts

No­vo Nordisk takes aim at Roche in he­mo­phil­ia A, but is way be­hind

Sion­na inks $191M IPO for cys­tic fi­bro­sis pipeline as Aard­vark eyes $89M for its own list­ing

Pfiz­er hires No­var­tis on­col­o­gy ex­ec to steer its can­cer am­bi­tions

A service from the Financial Times